Cargando…

Response to R. Waldman et al.: ‘Does IL‐4 inhibition play a role in dupilumab‐associated conjunctivitis?’

Linked Article: Waldman et al. Br J Dermatol 2020; 182:251. Bakker et al. Br J Dermatol 2019; 180:1248–9.

Detalles Bibliográficos
Autores principales:	Ardeleanu, M., Shumel, B., Rossi, A.B., Graham, N.M.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317488/ https://www.ncbi.nlm.nih.gov/pubmed/31853960 http://dx.doi.org/10.1111/bjd.18808

Ejemplares similares

Conjunctivitis in dupilumab clinical trials
por: Akinlade, B., et al.
Publicado: (2019)

Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal Volunteers
por: Kovalenko, P, et al.
Publicado: (2016)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
por: Wollenberg, A., et al.
Publicado: (2019)

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials
por: Blauvelt, A., et al.
Publicado: (2019)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2020)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
por: Ferreira, Sandra, et al.
Publicado: (2020)

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
por: Silverberg, J.I., et al.
Publicado: (2019)

Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis
por: Di Staso, Federico, et al.
Publicado: (2022)

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
por: Hamilton, Jennifer D., et al.
Publicado: (2021)

Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials
por: Katoh, N., et al.
Publicado: (2019)

A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis
por: Agnihotri, Gaurav, et al.
Publicado: (2019)

Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis
por: Callewaert, Chris, et al.
Publicado: (2019)

Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report
por: Adachi, Rumi, et al.
Publicado: (2022)

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
por: Thyssen, J.P., et al.
Publicado: (2019)

Transient Increase in Circulating Basophils and Eosinophils in Dupilumab-associated Conjunctivitis in Patients with Atopic Dermatitis
por: KATSUTA, Michie, et al.
Publicado: (2021)

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2020)

Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy
por: Kimura, Ayaka, et al.
Publicado: (2021)

Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension
por: Cork, M.J., et al.
Publicado: (2019)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
por: Wu, Jashin J., et al.
Publicado: (2021)

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Yosipovitch, Gil, et al.
Publicado: (2021)

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2021)

Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab–Associated Conjunctivitis in Patients with Atopic Dermatitis
por: Patra, VijayKumar, et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2022)

Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
por: Armstrong, April, et al.
Publicado: (2021)

Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps
por: Kariyawasam, Harsha H, et al.
Publicado: (2020)

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
por: Le Floc’h, Audrey, et al.
Publicado: (2020)

Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials
por: Beck, L.A., et al.
Publicado: (2020)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older
por: Simpson, Eric L., et al.
Publicado: (2021)

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020)

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
por: Paller, A.S., et al.
Publicado: (2020)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2021)

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
por: Kimball, Alexa B., et al.
Publicado: (2023)

Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
por: Piazzetta, Giovanna Lucia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tthdcp5bb7r0342koqp8p5ojl4